The stock of Zimmer Biomet Holdings Inc. (NYSE:ZBH) increased by $1.95 on Wednesday to $117.28, up 1.69 percent. The last five days have seen an average of 771,831 shares of common stock traded. 5 times new highs were reached in the current year, with a fall of -$9.54. The average number of shares traded over the last 20 days was 1,235,193, while the average volume over the last 50 days totaled 1,144,803.
ZBH stock appreciated 5.78% since last month. On 11/04/22, the company’s shares reached a one-month low of $103.75. The stock touched a high of $135.05 on 04/21/22, after rallying from a low of $100.39 in 52 weeks. The price of ZBH stock has declined by -6.42% or -$9.54 this year, reaching a new high 5 times. Still, the stock price is down -13.16% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
ZBH stock investors should be aware that Zimmer Biomet Holdings Inc. (ZBH) stock had its last reported insider trading activity 141 days ago on Jul 05. On Jul 05, Pres, Europe, M. East & Africa VAN ZUILEN WILFRED sold 531 shares at $105.22 each. This transaction resulted in the insider making $55,870. On Mar 17, Phipps Chad F sold 35,149 shares at a price of US$121.97. After the transaction, the insider now owns 41,539 shares. President, Asia Pacific Yi Sang had earlier sold 2,800 shares on Dec 14 for $124.14 a share. The transaction was completed for $347,599.
Zimmer Biomet Holdings Inc. (ZBH) has a trailing price-to-earnings (P/E) ratio of 71.77. Beta for the stock is 1.09. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.33, the price-to-book (PB) ratio of 1.98, and the price-to-cash flow ratio of 23.71.
Company paid $0.24 per share in dividends, remained unchanged from $0.24 last year. A $0.02 dividend increase was reported on Wednesday February 24 2016.
For the three months ended September 29, Zimmer Biomet Holdings Inc.’s quick ratio was 1.00, while its current ratio was 2.00, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending September 29 is 0.41, and the total debt to equity ratio is 0.47. As far as profitability goes, gross margin for the trailing twelve months is 69.80% percent. Zimmer Biomet Holdings Inc.’s operating margin stood at 8.90% for the same period. Based on annual data, it had gross profit of $5.5 billion and revenue of $7.84 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ZBH’s return on assets (ROA) during the last 12 months has been 1.30%. There was a 3.20% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 2.30%.
According to Zimmer Biomet Holdings Inc.’s quarterly financial report for the quarter that ended September 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.67 billion, while revenues fell by -15.22% to $1.78 billion. It was predicted that Zimmer Biomet Holdings Inc.’s quarterly earnings would be $1.58, but it ended up being $1.55, beating the consensus by 1.90%. EBITDA was $476.7 million for the quarter. At the end of Zimmer Biomet Holdings Inc.’s most recent quarter ended September 29, its liabilities totaled 9.08 billion, while its total debt was $5.9 billion. Equity owned by shareholders amounts to $209.85 million.
Here’s a quick look at Zimmer Biomet Holdings Inc.’s (ZBH) price momentum from a technical perspective. As of 22 November, the RSI 9-day stood at 66.36%, suggesting the stock is Neutral, with a 24.42% historical volatility rate.
The stochastic %K and %D were 94.23% and 87.96% respectively, while the average true range (ATR) was 2.74. Based on the 14-day stochastic reading of 99.71%, the RSI (14) reading is 61.89%. On the 9-day MACD Oscillator, the stock is at 1.12, and the 14-day reading is at 3.69.
In its most recent analyst report, Wells Fargo raised its rating on Zimmer Biomet Holdings Inc. (NYSE: ZBH) to an Equal weight. Prior to this, analysts firm rated the stock as an Underweight. Analysts have assigned Zimmer Biomet Holdings Inc. (ZBH) an Hold rating. ZBH is a stock that is recommended for selling by 2 brokerage firms, while 17 companies recommend holding. The stock is underweighted by 2 analysts. Among the analysts who rate the stock, 1 rate it overweight and 6 others recommend it as a buy.
What is ZBH’s price target for the next 12 months?
The current consensus forecast for the stock is between $100.00 and $145.00, with a median target price of $120.50. In analyzing these forecasts, the average price target given by analysts for Zimmer Biomet Holdings Inc. (ZBH) is $122.73.